Perrigo CO PLC Form 4 insider transactions

EVP and Chief Medical Officer of Perrigo, Grainne Quinn, reports acquiring 6,210 restricted stock units.

Perrigo Company plc CEO Patrick Lockwood-Taylor reports the acquisition of 53,503 Restricted Stock Units (RSUs) and the disposal of 20,500 ordinary shares.

Eduardo Guarita Bezerra, EVP & Chief Financial Officer of Perrigo Co plc, reports acquisition of restricted stock units.

EVP and CIO of Perrigo Company, Thomas Farrington, reports the acquisition of 6,640 restricted stock units.

EVP & CHRO of Perrigo Company plc, Robert Willis, reports the acquisition of 6,210 restricted stock units on April 5, 2024.

Ronald Craig Janish, EVP at Perrigo, reports acquisition of restricted stock units and updates to beneficial ownership of ordinary shares.

EVP & Chief Scientific Officer of Perrigo Company plc, Alison Ives, reports the acquisition of 7,166 Restricted Stock Units (RSUs) on April 5, 2024.

EVP & General Counsel of Perrigo, Kyle Hanson, reports the acquisition of 12,420 Restricted Stock Units (RSUs) on April 5, 2024.

EVP and Chief Medical Officer of Perrigo, Grainne Quinn, reports acquisition and disposal of ordinary shares and restricted stock units.

EVP & CHRO of Perrigo, Robert Willis, reports acquisition and disposal of ordinary shares and restricted stock units.

Ronald Craig Janish, EVP at Perrigo, reports acquisition and disposal of ordinary shares and restricted stock units.

EVP & General Counsel of Perrigo, Kyle Hanson, reports acquisition and disposal of ordinary shares and restricted stock units.

Thomas Farrington, EVP and CIO of Perrigo, reports the vesting of restricted stock units and subsequent tax withholding.

Eduardo Guarita Bezerra, EVP & CFO of Perrigo Company plc, reports the acquisition and disposal of ordinary shares and vesting of restricted stock units on March 6, 2024.

Alison Ives, EVP & Chief Scientific Officer of Perrigo Co. plc, reports acquisition and disposal of ordinary shares and restricted stock units.

Svend Andersen, EVP & President CHCI at Perrigo Co plc, reports acquisition of shares through restricted stock unit vesting.

EVP & Chief Scientific Officer of Perrigo, Alison Ives, reports acquisition and disposal of ordinary shares and restricted stock units on March 5, 2024.

Alison Ives, EVP & Chief Scientific Officer of Perrigo Co plc, reports the acquisition of 1,545 ordinary shares at $26.44 per share on February 29, 2024.

Alison Ives, EVP & Chief Scientific Officer of Perrigo, files an amended Form 4 to correct an underreporting of share ownership following a transaction on November 16, 2023.

Ronald Craig Janish, EVP at Perrigo, reports acquisition and disposal of ordinary shares on March 5, 2024, according to a Form 4 filing.

EVP & CHRO of Perrigo, Robert Willis, reports transactions involving ordinary shares and restricted stock units.

EVP and Chief Medical Officer of Perrigo, Grainne Quinn, reports transactions involving ordinary shares and restricted stock units.

Thomas Farrington, EVP and CIO of Perrigo, reports transactions involving ordinary shares and restricted stock units.

EVP and President of Consumer Self-Care International at Perrigo, Svend Andersen, reports acquisition of ordinary shares and activity related to Restricted Stock Units (RSUs).

Julia M. Brown, a director at Perrigo Company plc, reported the acquisition of 5,548 restricted stock units (RSUs) on March 5, 2024, according to a Form 4 filing with the SEC.

Robert Willis, EVP & CHRO of Perrigo Co plc, reports the acquisition of ordinary shares on February 29, 2024, and March 1, 2024.

Perrigo Company plc CEO Patrick Lockwood-Taylor reports the acquisition of 9,500 ordinary shares on February 29, 2024.